ArticleNature protocols2015
Direct conversion of human amniotic cells into endothelial cells without transitioning through a pluripotent state.
Article in Nature protocols, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Dissecting endothelial cell heterogeneity with new tools.Cell regeneration (London, England) · 2025Review
- Sources and applications of endothelial seed cells: a review.Stem cell research & therapy · 2024Review
- Somatic Lineage Reprogramming.Cold Spring Harbor perspectives in biology · 2022Review
- Etv2 regulates enhancer chromatin status to initiate Shh expression in the limb bud.Nature communications · 2022Article
- Differential Etv2 threshold requirement for endothelial and erythropoietic development.Cell reports · 2022Article
- A Hybrid Nanofiber/Paper Cell Culture Platform for Building a 3D Blood-brain Barrier Model.Small methods · 2021Article
- Pluripotent stem cell-derived epithelium misidentified as brain microvascular endothelium requires ETS factors to acquire vascular fate.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Hypoxia-induced amniotic fluid stem cell secretome augments cardiomyocyte proliferation and enhances cardioprotective effects under hypoxic-ischemic conditions.Scientific reports · 2021Article
- Article
- Direct cell reprogramming for tissue engineering and regenerative medicine.Journal of biological engineering · 2019Review
- In vitro conversion of adult murine endothelial cells to hematopoietic stem cells.Nature protocols · 2018Article
- Amniotic fluid cells: current progress and emerging challenges in renal regeneration.Pediatric nephrology (Berlin, Germany) · 2018Review
- Cooperation between ETS variant 2 and Jumonji domain‑containing 2 histone demethylases.Molecular medicine reports · 2018Article
- Regenerating the Cardiovascular System Through Cell Reprogramming; Current Approaches and a Look Into the Future.Frontiers in cardiovascular medicine · 2018Review
- Whole Organ Tissue Vascularization: Engineering the Tree to Develop the Fruits.Frontiers in bioengineering and biotechnology · 2018Review
- Extracellular vesicles of ETV2 transfected fibroblasts stimulate endothelial cells and improve neovascularization in a murine model of hindlimb ischemia.Cytotechnology · 2017Article
- Etv2 as an essential regulator of mesodermal lineage development.Cardiovascular research · 2017Review
- GATA4-dependent organ-specific endothelial differentiation controls liver development and embryonic hematopoiesis.The Journal of clinical investigation · 2017Article
- Effects of serum starvation and vascular endothelial growth factor stimulation on the expression of Notch signalling pathway components.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Endothelial cells (ECs) have essential roles in organ development and regeneration, and therefore they could be used for regenerative therapies. However, generation of abundant functional endothelium from pluripotent stem cells has been difficult because ECs generated by many existing strategies have limited proliferative potential and display vascular instability. The latter difficulty is of particular importance because cells that lose their identity over time could be unsuitable for therapeutic use. Here, we describe a 3-week platform for directly converting human mid-gestation lineage-committed amniotic fluid-derived cells (ACs) into a stable and expandable population of vascular ECs (rAC-VECs) without using pluripotency factors. By transient expression of the ETS transcription factor ETV2 for 2 weeks and constitutive expression the ETS transcription factors FLI1 and ERG1, concomitant with TGF-β inhibition for 3 weeks, epithelial and mesenchymal ACs are converted, with high efficiency, into functional rAC-VECs. These rAC-VECs maintain their vascular repertoire and morphology over numerous passages in vitro, and they form functional vessels when implanted in vivo. rAC-VECs can be detected in recipient mice months after implantation. Thus, rAC-VECs can be used to establish a cellular platform to uncover the molecular determinants of vascular development and heterogeneity and potentially represent ideal ECs for the treatment of regenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.